Italian Society of Cardiology, prestigious national appointment to Sienese doctor Alberto Palazzuoli
The Sienese cardiologist Alberto Palazzuoli is the new national coordinator of the study group on heart failure, appointed by the Italian Society of Cardiology (SIC) during the congress held in Rome. The prestigious professional and scientific recognition will be valid for three years starting from 2023: Palazzuoli currently holds the position of director of UOSA (autonomous simple operating unit) Cardiovascular Diseases of the Sienese university hospital. The appointment he has received follows a previous assignment obtained last October as a member of the working group of Imaging from the Heart Failure Association of the European Society of Cardiology. The Sienese professor had already distinguished himself last year with two publications, which appeared in two prestigious American journals in collaboration with the study group he currently chairs and with the universities of New Orleans and Charlottesville. In his role as national coordinator, Palazzuoli will take care of the design of studies and clinical and research protocols for the improvement of diagnostics and therapy of patients suffering from heart failure with the modern discipline based on the ” precision medicine”, as well as promoting a series of scientific meetings throughout Italy focused on the early recognition of the disease and the role of risk factors. Dr. Palazzuoli says: “Personal satisfaction with the achievement of the title is associated with a potential benefit for patients suffering from heart failure, as well as with the recognition of skills established at national level who work within the Sienese hospital of which the citizens can benefit by contacting the public health service in our area”. The Operating Unit directed by Professor Palazzuoli guarantees the Siena hospital a cardiological service for patients with external cardiovascular pathologies or hospitalized through a clinical-diagnostic activity aimed in particular at patients suffering from heart failure aimed at clinical stabilization and reduction of hospitalizations that characterize this pathology.